Evidence map›Paper›PMID 37154984›Full record

ArticleJapanese journal of ophthalmology2023

Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.

Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Haruka Ochi, Shino Ohsawa, Annabelle Ayame Okada, TENAYA and LUCERNE Investigators

Open access · bronzeAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Ryusaburo MoriDepartment of Ophthalmology, Nihon University School of Medicine, 1-6 Surugadai, Kanda, Chiyodaku, Tokyo, 101-8309, Tokyo, Japan. mori.ryusaburo@nihon-u.ac.jp.
Shigeru HondaDepartment of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Fumi GomiDepartment of Ophthalmology, Hyogo Medical University, Hyogo, Japan.
Akitaka TsujikawaDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hideki KoizumiDepartment of Ophthalmology, University of the Ryukyus, Okinawa, Japan.
Haruka OchiChugai Pharmaceutical Co., Ltd, Tokyo, Japan.
Shino OhsawaChugai Pharmaceutical Co., Ltd, Tokyo, Japan.
Annabelle Ayame OkadaDepartment of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
TENAYA and LUCERNE Investigators
Hyogo University · JPKyorin University · JPKyoto University · JPOsaka Metropolitan UniversitySurugadai Nihon University Hospital · JPUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37154984
PMCPMC10320790
OpenAlexW4375864844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.